摘要
基于现代科学技术及理念的创新中药研究并没有脱离传统天然药物研究思路,在继承与创新中医药理论体系中,基本没有继承,创新又不足,使创新中药新药研究陷入一种尴尬境地。我们在总结"十一五"、"十二五"课题经验的同时,结合即将开展的"十三五"组分中药的研发思路,分析了影响中药新药现代化研究的3个问题并提出了解决的方法:(1)高水平候选处方的科学筛选始终是中药新药研制的瓶颈,是中药现代化的基本前提;(2)大力开展中药转化医学研究,制定科学、合理的中药转化模式是推动中药现代化的重要出路和举措;(3)从组分中药剂型发展和改革的角度,需要遵循传统中医基础理论,综合考虑组分中药成药性的特点,给组分中药剂型的筛选和研发奠定基础。
Based on the innovation of modern science and technology and concepts, the study of innovative Chinese medicine research has not been divorced from the traditional thinking of natural medicine research, in the theoretical system of traditional Chinese medicine, there was basically no inheritance and lack of innovation, which made the research of new medicine of traditional Chinese medicine fall into an awkward position. We sum up our experience in11 th Five-Year and 12 th Five-Year, combined with the upcoming 13 th Five-Year of the research and development idea of component Chinese Medicine, analyzed the impact of 3 aspects on the modernization of Chinese traditional medicine and put forward the solving methods.（1） The scientific screening of high-level candidate prescriptions has always been the bottleneck of the development of new Chinese medicine and the basic premise of modernization of Chinese Medicine;（2） It is an important outlet and measure to promote the modernization of traditional Chinese medicine to vigorously carry out the research on the transformation of traditional Chinese medicine and to formulate a scientific and rational mode of transformation of traditional Chinese medicine;（3） From the point of view of the development and reform of component traditional Chinese medicine, it is necessary to follow the basic theory of traditional Chinese medicine, and comprehensively to consider the characteristics of the components of Chinese medicine, and to lay the foundation for the screening and research and development of Chinese herbal medicines
出处
《世界科学技术-中医药现代化》
CSCD
2017年第9期1419-1423,共5页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
科学技术部"十三五"国家重大新药创制科技重大专项(2017ZX09301019):基于组分中药创新模式的射干新药开发研究
负责人:李国信
关键词
处方筛选
转化医学
组分中药
方法学
Prescription screening
translational medicine
Component Chinese Medicine
Methodology
